Clinical Trial Update: Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigated the combination of tipifarnib and bortezomib in relapsed multiple myeloma, but the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED